Blood tests may vary in measuring factor VIII after treatment
Blood tests can give different readings of factor VIII (FVIII) activity after treatment with Altuvoct (efanesoctocog alfa), marketed as Altuviiio in the U.S., a study found. The di...
Blood tests can give different readings of factor VIII (FVIII) activity after treatment with Altuvoct (efanesoctocog alfa), marketed as Altuviiio in the U.S., a study found. The di...
Bleeding that persists or restarts after dental procedures may be an important warning sign of previously undiagnosed mild hemophilia, a systematic review of published case reports...
Circulating extracellular matrix protein fragments are elevated in young adults one to seven years after surgically managed knee injury compared to matched controls.
Artificial intelligence (AI) shows promise for helping doctors diagnose hemophilia, detect joint complications, and predict disease severity and other clinical outcomes, a review o...
More people are being identified with hemophilia B across the eastern Mediterranean region, suggesting improvements in hemophilia diagnosis and reporting, according to a study anal...
Once-weekly preventive treatment with Altuviiio (efanesoctocog alfa) safely reduced bleeding rates while maintaining protective clotting factor levels without triggering neutralizi...
Liver enzyme levels may rise again as corticosteroid doses are gradually reduced in people with hemophilia B treated with Hemgenix, a case report suggests. Elevated liver enzymes a...
Preventive treatment with Hemlibra (emicizumab-kxwh) kept bleeding under control for nearly three years in people with mild or moderate hemophilia A without inhibitors. That’s acco...
A temporal-validation study of 847 stroke patients found that clinical severity and established risk factors predicted hemorrhagic transformation more reliably than routine inflamm...
Preventive treatment with low-dose Hemlibra (emicizumab-KXWH) significantly reduced bleeding and improved quality of life in young children with hemophilia A, regardless of inhibit...
Inno8, a potential oral treatment to prevent bleeds in people with hemophilia A, appears more potent and long-lasting than currently available injectable treatments in preclinical...
A large prospective UK Biobank study of 52,584 adults identified nine plasma proteins, led by neurofilament light chain, that predict ALS onset up to a decade before symptoms, with...
A small study in Japan suggests that younger women identified as hemophilia carriers have greater access to information and specialized care than women in an earlier generation, bu...
By educating and empowering patients and their families, clinicians can help improve access to accurate diagnoses and care for women and girls affected by hemophilia. That’s the ar...
The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or without inhibitors — has been approved in the European Union...
Every new hematologist asks the same question: “Who else in your family has it?” For most of my life, the answer was nobody. Nobody with a diagnosis, anyway. I was diagnosed with h...
The U.S. Food and Drug Administration (FDA) has given the go-ahead for Metagenomi Therapeutics to start a first-in-human clinical trial testing MGX-001, the company’s experimental...
by Cristian Groza, Arnaud Chignon, Ken Sin Lo, Vanessa Bellegarde, Pablo Bartolucci, Guillaume Lettre There are few therapeutic options to treat patients with sickle cell disease...
A large MIMIC-IV study finds that a low hemoglobin-to-red cell distribution width ratio is associated with diabetic kidney disease in critically ill patients with type 2 diabetes.
Hemophilia A patients rack up high hospital bills, driving costs for the healthcare system higher, a study from Canada showed. “This study confirms that even with improved [treatme...
The study, led by two specialists from Oxford University Hospitals (OUH), will explore whether a naturally occurring joint fluid could reduce pain.
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
The recent wave of IgAN trials has reinforced galactose-deficient IgA1 (Gd-IgA1) as a mechanistic/pharmacodynamic biomarker, but not as a validated diagnostic or monitoring test. A...
More than half of people with hemophilia receiving prophylactic (preventive) factor replacement therapies at two treatment centers in Brazil did not collect enough medication to fo...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.